Risk of Increased Respiratory Adverse Reactions
ARIKAYCE has been associated with a risk of increased respiratory adverse reactions, including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.
Patient counseling
Medical guidelines
Package inserts
Additional information
Keywords: Arikayce
Updated: October 2018
This information provides a SUMMARY of Black Box data from product labeling and does not address all warnings, precautions, or important safety data found in the product insert. It is NOT intended for use in medical decision-making. Patients and healthcare professionals should always consult the most recent product information insert available from the manufacturer, and contact a physician or care provider with any questions. This table may not be complete and may not include all boxed warnings. It is periodically updated with supplemental information from FDA safety alerts, labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.